Lexington Biosciences Inc. (LXGTF)

[Bigphilly]

THOMSON REUTERS*

NEW BRUNSWICK, N.J., Jan. 17, 2019 /PRNewswire/ -- Johnson & Johnson
(NYSE: JNJ) today announced that Janssen Pharmaceuticals, Inc., member of the
Johnson & Johnson Family of Companies, entered into a research study in
collaboration with Apple Inc. to investigate whether a new heart health
program using an app from Johnson & Johnson in combination with Apple
Watch's irregular rhythm notifications and ECG app can accelerate the
diagnosis and improve health outcomes of the 33 million people worldwide
living with atrial fibrillation (AFib), a condition that can lead to stroke
and other potentially devastating complications. In the U.S. alone, AFib is
responsible for approximately 130,000 deaths and 750,000 hospitalizations
every year.

The study aims to analyze the impact of Apple Watch on the early detection and
diagnosis of AFib, and the potential to improve outcomes including the
prevention of stroke. A multi-year research program will be launched later in
2019. This large-scale program will occur in the U.S. only, and will be
designed as a pragmatic randomized controlled research study for individuals
age 65 years or older.

The study's goals include:

* Measuring the outcomes of a heart health engagement program with irregular
rhythm notifications on Apple Watch.
* Assessing the impact of a medication adherence program using an app from
Johnson & Johnson.
"We're excited about the potential of common, wearable technology to aid in
the earlier detection and prevention of a frequent cause of stroke," said Paul
Stoffels, M.D., Vice Chair of the Executive Committee and Chief Scientific
Officer, Johnson & Johnson. "Too many people living with AFib are unaware
of their risk, and earlier detection, diagnosis and treatment of AFib could
significantly improve outcomes. Based on the insights generated through this
research program, we may be able to develop new ways to detect other health
conditions earlier in the future that also exhibit measurable physiological
symptoms."

"Through Apple Watch people have been able to learn more about their heart
health, including discovering they have AFib. This kind of information
empowers customers to follow up with the right treatment or even better,
implement healthy habits aimed at prevention," said Jeff Williams, Chief
Operating Officer, Apple Inc. "We're excited to work with Johnson &
Johnson, a leader in the medical community, as we learn about the impact
Apple Watch can have in delivering better health outcomes."

Johnson & Johnson's recent mSTOPs (mHealth Screening to Prevent Strokes)
study demonstrated that earlier screening leads to increased AFib detection.
"Utilizing wristwatch-based optical heart sensor and ECG monitoring is a
logical evolution of this research and may also lead to increased AFib
diagnosis and improved clinical outcomes for patients," said Paul Burton,
M.D., Ph.D., FACC, Vice President, Medical Affairs, Internal Medicine, Janssen
Scientific Affairs, LLC. "This collaboration brings together Johnson &
Johnson's depth of expertise and long heritage in treating cardiovascular
disease with Apple's experience in utilizing cutting-edge technologies to
improve the lives of consumers. Ultimately, we hope to improve the treatment
of cardiovascular disease, and identify ways to prevent it."

About AFib
AFib is an irregular heartbeat that can lead to the formation of blood clots
resulting in stroke, heart failure and other potentially devastating
complications. AFib is the most common sustained arrhythmia, increases stroke
risk five-fold, and accounts for almost one-third of all strokes.[ii] Because
blood clots formed in the heart can be large, AFib-caused strokes tend to
damage large areas of the brain, which typically leads to a higher risk of
death, significant damage and increased cost of treatment and care. Around 20%
of individuals who experience a stroke were not aware of their underlying AFib
condition.[iii]

About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant
lives, thriving communities and forward progress. That's why for more than 130
years, we have aimed to keep people well at every age and every stage of life.
Today, as the world's largest and most broadly-based health care company, we
are committed to using our reach and size for good. We strive to improve
access and affordability, create healthier communities, and put a healthy
mind, body and environment within reach of everyone, everywhere. We are
blending our heart, science and ingenuity to profoundly change the trajectory
of health for humanity.

About the Janssen Pharmaceutical Companies of Johnson & Johnson
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are
working to create a world without disease. Transforming lives by finding new
and better ways to prevent, intercept, treat and cure disease inspires us. We
bring together the best minds and pursue the most promising science. We are
Janssen. We collaborate with the world for the health of everyone in it. Learn
more at www.janssen.com
(https://c212.net/c/link/?t=0&l=en&o=2348861-1&h=557286647&u=http%3A%2F%2Fwww.janssen.com%2F&a=www.janssen.com)
. Follow us at @JanssenGlobal
(https://c212.net/c/link/?t=0&l=en&o=2348861-1&h=2250372902&u=https%3A%2F%2Ftwitter.com%2FJanssenGlobal&a=%40JanssenGlobal)
. Janssen Pharamaceuticals, Inc. is part of the Janssen Pharmaceutical
Companies of Johnson & Johnson.

Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995 regarding the collaboration
with Apple Inc. seeing to advance research and the development of healthcare
solutions and technologies. The reader is cautioned not to rely on these
forward-looking statements. These statements are based on current expectations
of future events. If underlying assumptions prove inaccurate or known or
unknown risks or uncertainties materialize, actual results could vary
materially from the expectations and projections of Janssen Pharmaceuticals,
Inc., any of the other Janssen Pharmaceutical Companies of Johnson &
Johnson and/or Johnson & Johnson. Risks and uncertainties include, but are
not limited to: the potential that the expected benefits and opportunities
related to the collaboration may not be realized or may take longer to realize
than expected; challenges inherent in new product development, including the
uncertainty of clinical success and obtaining regulatory approvals;
competition, including technological advances, new products and patents
attained by competitors; uncertainty of commercial success for new products;
the ability of the company to successfully execute strategic plans; impact of
business combinations and divestitures; challenges to patents; changes in
behavior and spending patterns or financial distress of purchasers of health
care products and services; and global health care reforms and trends toward
health care cost containment. A further list and descriptions of these risks,
uncertainties and other factors can be found in Johnson & Johnson's Annual
Report on Form 10-K for the fiscal year ended December 31, 2017, including in
the sections captioned "Cautionary Note Regarding Forward-Looking
Statements" and "Item 1A. Risk Factors," in the company's most recently filed
Quarterly Report on Form 10-Q, and the company's subsequent filings with the
Securities and Exchange Commission. Copies of these filings are available
online at www.sec.gov (http://www.sec.gov) , www.jnj.com (http://www.jnj.com)
or on request from Johnson & Johnson. Neither the Janssen Pharmaceutical
Companies nor Johnson & Johnson undertakes to update any forward-looking
statement as a result of new information or future events or developments.